J
James A. Talcott
Researcher at Harvard University
Publications - 103
Citations - 8404
James A. Talcott is an academic researcher from Harvard University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 38, co-authored 100 publications receiving 8018 citations. Previous affiliations of James A. Talcott include University of Texas MD Anderson Cancer Center & American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients
Jean Klastersky,Marianne Paesmans,Edward B. Rubenstein,Michael Boyer,Linda S. Elting,Ronald Feld,James J. Gallagher,Jorn Herrstedt,Bernardo Leon Rapoport,Kenneth V. I. Rolston,James A. Talcott +10 more
TL;DR: The risk index accurately identifies patients at low risk for complications and may be used to select patients for testing therapeutic strategies that may be more convenient or cost-effective.
Journal ArticleDOI
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.
Edward Giovannucci,Meir J. Stampfer,Krishna Krithivas,Myles Brown,Adam Brufsky,James A. Talcott,Charles H. Hennekens,Philip W. Kantoff +7 more
TL;DR: It is demonstrated that a shorter CAG repeat sequence in the androgen receptor gene predicts higher grade and advanced stage of prostate cancer at diagnosis, and metastasis and mortality from the disease.
Journal ArticleDOI
Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline
D. Andrew Loblaw,Katherine S. Virgo,Robert Nam,Mark R. Somerfield,Edgar Ben-Josef,David S. Mendelson,Richard Middleton,Stewart A. Sharp,Thomas J. Smith,James A. Talcott,Mary-Ellen Taplin,Nicholas J. Vogelzang,James L. Wade,Charles L. Bennett,Howard I. Scher +14 more
TL;DR: Bilateral orchiectomy or luteinizing hormone-releasing hormone agonists are recommended initial androgen-deprivation treatments (ADTs) and data are insufficient to support use of intermittent androgen blockade outside clinical trials.
Journal ArticleDOI
Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.
TL;DR: This risk assessment model accurately stratified the medical risk of cancer patients with fever and neutropenia using only clinical information available on the first day of their course and confirmed low-risk patients are an appropriate population in which to study less intensive treatment strategies.
Journal ArticleDOI
The Medical Course of Cancer Patients With Fever and Neutropenia Clinical Identification of a Low-Risk Subgroup at Presentation
TL;DR: It may be possible to assess the medical stability of patients with fever and neutropenia based on presenting clinical features to enable clinicians to identify groups of medically stable patients for whom conventional supportive care may be given safely under medical supervision of less intensity or of shorter duration than conventional treatment in the acute-care hospital setting.